infecti
agent
associ
communityacquir
pneumonia
cap
understudi
studi
attempt
identifi
virus
upper
respiratori
tract
adult
visit
emerg
depart
clinic
suspect
cap
adult
suspect
cap
enrol
escap
studi
impact
comput
tomographi
cap
diagnosi
prospect
nasopharyng
np
sampl
studi
multiplex
pcr
target
virus
four
intracellular
bacteria
adjud
committe
compos
infecti
diseas
specialist
pneumologist
radiologist
blind
pcr
result
review
patient
record
includ
comput
tomographi
day
follow
categor
final
diagnost
probabl
cap
definit
probabl
possibl
exclud
among
patient
enrol
posit
pcr
detect
virus
intracellular
bacteria
patient
pcr
posit
patient
definit
cap
patient
exclud
cap
frequent
organ
influenza
ab
viru
rhinoviru
coronaviru
seven
respiratori
syncyti
viru
seven
mycoplasma
pneumonia
eight
patient
proport
rhinoviru
higher
patient
exclud
cap
compar
diagnost
categori
p
differ
observ
influenza
viru
virus
seem
common
adult
attend
emerg
depart
suspect
cap
concomit
clinic
radiolog
biolog
analysi
patient
chart
contribut
either
confirm
role
suggest
upper
respiratori
tract
infect
shed
imput
impact
earli
manag
cap
deserv
studi
clinic
trial
registr
clinic
microbiolog
infect
communityacquir
pneumonia
cap
increasingli
recogn
lead
caus
hospit
admiss
death
among
adult
industri
countri
one
common
infecti
diseas
encount
emerg
depart
ed
annual
incid
estim
case
per
inhabit
repres
franc
around
case
per
year
caus
annual
death
particularli
elderli
popul
current
diagnosi
cap
heavili
depend
clinic
radiolog
find
larg
nonspecif
unknown
aetiolog
treatment
remain
case
empir
convent
microbiolog
techniqu
cultur
serolog
antigen
detect
practic
challeng
notabl
complex
technolog
poor
sensit
prolong
turnaround
time
sinc
advent
pcr
advanc
new
molecular
techniqu
shown
applic
improv
detect
agent
caus
variou
type
infect
multiplex
pcr
method
allow
potenti
amplif
mani
nucleic
acid
target
within
singl
reaction
proven
attract
diagnost
method
multipathogen
detect
respiratori
tract
infect
ed
time
accur
diagnosi
crucial
treatment
decis
outcom
patient
advoc
prognosi
cap
depend
immedi
initi
specif
treatment
later
h
diagnosi
present
identif
infecti
agent
use
multiplex
pcr
adult
patient
suspect
cap
visit
ed
franc
within
framework
escap
studi
prospect
openlabel
multicentr
impact
measur
studi
thorac
comput
tomographi
ct
scan
primari
object
present
microbiolog
studi
determin
preval
infecti
agent
virus
bacteria
nasopharyng
np
swab
use
multiplex
pcr
adult
present
clinic
suspect
nonsever
cap
studi
also
aim
describ
detect
pathogen
accord
probabl
diagnosi
cap
escap
studi
conduct
four
univers
hospit
bichat
cochin
tenon
pari
franc
studi
approv
ethic
committe
de
protect
de
personnescpp
pari
franc
patient
gave
written
inform
consent
consecut
adult
patient
year
present
hospit
ed
clinic
suspicion
nonsever
cap
class
score
prospect
enrol
clinic
suspicion
cap
base
investig
judgement
fulfil
follow
criteria
new
onset
system
featur
least
one
among
sweat
fever
chill
ach
pain
temperatur
symptom
acut
lower
respiratori
tract
ill
least
one
among
cough
sputum
product
dyspnoea
chest
pain
alter
breath
sound
expert
adjud
committe
compris
senior
infecti
diseas
specialist
pneumologist
radiologist
review
patient
record
use
clinic
data
includ
day
follow
radiolog
thorac
xray
ct
scan
perform
ed
admiss
laboratori
find
assess
diagnosi
cap
posteriori
jointli
establish
diagnosi
cap
final
diagnost
probabl
accord
four
categoriesdefinit
probabl
possibl
exclud
cap
committe
blind
pcr
result
systemat
np
swab
collect
enrol
nose
also
throat
subpopul
patient
place
middl
virocult
mwe
sigma
st
loui
mo
usa
transport
medium
sampl
kept
room
temperatur
sent
virolog
laboratori
bichatclaud
bernard
hospit
soon
possibl
collect
np
sampl
use
studi
frozen
thaw
sampl
blood
urin
sputum
collect
bacteriolog
examin
within
scope
routin
care
indic
attend
physician
assay
pathofind
maastricht
netherland
use
detect
respiratori
virusescoronavirus
human
metapneumoviru
influenza
b
virus
parainfluenza
virus
respiratori
syncyti
virus
b
rhinoviru
adenoviru
four
intracellular
bacteriabordetella
pertussi
chlamydophila
pneumonia
legionella
pneumophila
mycoplasma
pneumoniaein
one
reaction
analys
amplifi
pcr
product
capillari
electrophoresi
use
dna
analys
abi
appli
biosystem
darmststadt
germani
provid
diagnosi
within
h
multiplex
pcr
method
use
present
studi
valid
virolog
lab
particip
everi
year
european
qualiti
control
program
respiratori
viru
data
collect
includ
demograph
variabl
gender
age
clinic
sign
cap
coexist
condit
sever
score
assess
fine
score
biolog
data
particular
inflammatori
biomark
continu
data
compar
use
student
test
analysi
varianc
mannwhitney
u
test
kruskalw
method
use
nonparametr
comparison
categor
variabl
proport
compar
use
chisquar
fisher
exact
test
statist
analys
perform
use
stata
softwar
version
statacorp
colleg
station
tx
usa
escap
studi
adult
patient
suspect
cap
enrol
novemb
decemb
patient
np
swab
avail
includ
studi
femal
mean
sd
age
year
baselin
characterist
pcr
studi
patient
shown
tabl
one
third
patient
belong
class
iv
class
v
fine
score
baselin
clinic
characterist
patient
without
swab
non
pcr
group
statist
differ
patient
underw
pcr
assay
pcr
studi
group
except
headach
frequent
patient
pcr
studi
group
impair
conscious
frequent
patient
non
pcr
group
among
patient
patient
least
one
infecti
agent
detect
fig
baselin
characterist
patient
differ
neg
pcr
result
tabl
except
neoplast
diseas
frequent
neg
pcr
group
vast
major
patient
n
singl
infecti
agent
total
pathogen
detect
patient
studi
patient
viru
detect
tabl
patient
posit
pcr
preval
viral
pathogen
influenza
ab
viru
rhinoviru
respiratori
syncyti
viru
ab
coronaviru
patient
virus
identifi
human
metapneumoviru
parainfluenza
virus
adenoviru
bacterium
detect
pneumonia
eight
patient
season
distribut
detect
pathogen
shown
fig
multiplex
pcr
detect
virus
np
sampl
concord
result
patient
np
swab
taken
central
virolog
laboratori
receiv
process
np
swab
within
h
probabl
pcr
posit
influenc
time
interv
np
swab
collect
pcr
test
pcr
posit
rate
viral
infect
agent
found
compar
np
nasal
sampl
abbrevi
ed
emerg
depart
neg
neg
po
posit
number
bold
p
valu
p
valu
calcul
use
test
otherwis
chisquar
test
use
predict
rule
assess
sever
communityacquir
pneumonia
clinic
microbiolog
infect
volum
number
june
among
patient
classifi
definit
cap
probabl
possibl
exclud
adjud
committe
tabl
although
pcr
find
differ
accord
diagnosi
probabl
among
patient
definit
cap
posit
pcr
result
pcr
neg
among
patient
exclud
cap
pcr
posit
probabl
pcr
detect
rhinovirus
significantli
higher
exclud
cap
three
group
combin
versu
respect
p
wherea
differ
detect
influenza
virus
versu
respect
refer
categori
diagnosi
sensit
specif
multiplex
pcr
posit
neg
predict
valu
respect
routin
bacteriolog
examin
avail
patient
bacteri
agent
detect
patient
probabl
nonpulmonari
infect
detect
bacteria
lung
tropism
possibl
associ
cap
tabl
streptococcu
pneumonia
nine
patient
legionella
pneumophila
intracellular
agent
three
patient
haemophilu
influenza
branhamella
catarrhali
gramposit
coccu
mycobacterium
tuberculosi
enterobacteriacea
one
patient
patient
bacteria
lung
tropism
definit
two
probabl
possibl
cap
accord
expert
bacterialvir
coinfect
present
seven
patient
proport
bacteri
document
differ
accord
antibiot
administr
admiss
ed
overal
cap
patient
detect
viral
bacteri
agent
possibl
respons
cap
present
studi
found
approxim
onethird
adult
ed
patient
present
suspect
cap
pcr
detect
virus
upper
respiratori
tract
mainli
influenza
ab
knowledg
first
prospect
clinic
trial
ed
describ
virus
associ
suspect
cap
adult
patient
take
account
adjud
committe
diagnosi
cap
refer
due
inadequ
accuraci
convent
diagnost
test
note
adjud
committe
base
judgement
followup
data
also
systemat
day
thorac
ct
scan
uniqu
valu
pcrposit
patient
definit
cap
agreement
sever
studi
without
adjud
committe
report
detect
virus
substanti
proport
patient
cap
jen
frequent
detect
virus
studi
influenza
ab
viru
rhinovirus
report
previou
studi
like
studi
report
address
patient
approxim
similar
rate
coexist
condit
paediatr
studi
identifi
viral
infect
realtim
pcr
hospit
patient
increas
asthma
frequenc
distribut
virus
detect
slightli
differ
two
recent
studi
patient
intens
care
unit
elderli
adult
moder
sever
ill
differ
may
partli
due
differ
virus
circul
commun
studi
period
sensit
specif
diagnost
technolog
use
season
distribut
detect
pathogen
studi
similar
observ
commun
french
surveil
network
patient
influenzalik
ill
v
enouf
institut
pasteur
person
commun
find
confirm
major
chang
induc
molecular
techniqu
describ
capassoci
microorgan
comparison
review
prospect
studi
ten
european
countri
approxim
patient
publish
wide
use
pcr
found
respiratori
virus
account
patient
cap
patient
definit
cap
diagnosi
rate
pcrposit
result
balanc
still
high
rate
neg
result
could
explain
viral
bacteri
fungal
agent
includ
target
assay
fact
np
sampl
proxi
infecti
agent
present
deeper
lung
consid
whether
lower
respiratori
sampl
would
clinic
microbiolog
infect
volum
number
june
facilit
imput
given
fewer
neg
result
studi
patient
sever
condit
allow
invas
diagnost
investig
import
admit
multiplex
pcr
may
differ
analyt
sensit
differ
virus
would
affect
diagnost
yield
interest
underlin
eight
patient
pcrdetect
pneumonia
definit
cap
reinforc
interest
test
context
pneumonia
epidem
pcrposit
patient
among
exclud
diagnosi
cap
might
explain
fact
infect
local
bronchi
upper
respiratori
tract
affect
pulmonari
parenchyma
could
also
explain
pcr
detect
viral
shed
patient
diseas
mimick
cap
symptom
studi
higher
proport
rhinovirus
patient
exclud
cap
suggest
least
part
rhinovirus
either
viral
shed
could
associ
limit
upper
respiratori
tract
infect
suggest
previous
symptomat
asymptomat
children
adult
season
distribut
influenza
ab
viru
detect
similar
proport
exclud
nonexclud
cap
suggest
pneumonia
primari
manifest
influenza
alreadi
known
anoth
hypothesi
high
rate
posit
pcr
exclud
cap
may
patient
minim
earli
lesion
cap
could
present
normal
ct
scan
known
long
time
chest
xray
epidemiolog
cap
adult
probabl
chang
recent
year
indirect
impact
pneumococc
conjug
vaccin
children
howev
establish
aetiolog
cap
remain
difficult
imput
pathogen
detect
upper
respiratori
tract
remain
question
present
studi
caus
determin
half
patient
even
consid
limit
relat
routin
nonstandard
sampl
bacteri
investig
studi
streptococcu
pneumonia
commonli
identifi
bacteria
associ
cap
gener
recogn
rate
detect
bacteria
atyp
agent
similar
report
recent
review
respiratori
virus
particularli
influenza
viru
respiratori
syncyti
viru
commonli
detect
patient
cap
describ
howev
remain
challeng
differenti
viral
cap
mixedinfect
bacteri
cap
hypothesi
increas
recognit
virus
caus
cap
adult
may
reflect
advanc
viral
detect
pcrbase
test
better
way
diagnos
viral
cap
would
increas
use
target
antivir
therapi
specif
detect
influenza
viru
lead
consider
antivir
therapi
within
h
onset
symptom
shown
improv
prognosi
use
establish
virolog
diagnosi
epidemiolog
purpos
hospit
patient
may
requir
infect
control
measur
prevent
nosocomi
transmiss
especi
case
new
andor
contagi
viru
outbreak
recent
middl
east
respiratori
syndrom
coronaviru
outbreak
whether
rapid
viral
diagnosi
like
chang
individu
antibiot
manag
reduc
antibiot
overus
studi
nevertheless
rel
low
sensit
test
high
cost
issu
need
address
widespread
use
multiplex
pcr
method
current
studi
sever
limit
multiplex
pcr
assay
perform
real
time
limit
may
underestim
identif
viral
agent
howev
assay
gener
consid
sensit
monoplex
pcr
suggest
delay
major
determin
falseneg
result
one
major
issu
pcr
test
includ
pneumonia
lead
organ
cap
target
preclud
comment
respect
role
pneumonia
virus
cap
agent
studi
use
sputum
sampl
adult
patient
attend
ed
yang
et
al
found
pcr
assay
might
use
diagnost
adjunct
clinician
detect
pneumococc
pneumonia
summari
virus
nasopharyng
sampl
seem
common
adult
attend
ed
suspect
cap
concomit
clinic
radiolog
biolog
analysi
patient
chart
contribut
either
confirm
role
cap
suggest
upper
respiratori
tract
infect
shed
imput
possibl
impact
earli
manag
cap
deserv
studi
studi
fund
french
ministri
health
phrc
aom
sponsor
assist
de
pari
chassani
c
miss
transpar
declar
dd
cl
potenti
conflict
